Key result
Indapamide-induced severe hypokalemia and hyponatremia were associated with the development of concomitant-acquired Long QT and Brugada syndromes in 1 patient.
Case Report (n=1)
This case highlights the potential role of hyponatremia in the pathogenesis of acquired Brugada syndrome, alongside hypokalemia-induced Long QT syndrome, following indapamide use.
Alerts clinicians to check electrolytes in at-risk patients; extends acquired Brugada precipitants but remains hypothesis-generating.
Electrolyte disturbances are known to cause acquired Long QT syndrome (LQTS) and Brugada syndrome. While a reduction in INa due to SCN5A mutation is implicated as the underlying mechanism in Brugada syndrome, hyponatremia, which can give rise to a reduced INa, has never been reported in literature as a cause or precipitating factor in this syndrome. We detailed a case in which concomitant-acquired LQTS and Brugada syndrome were associated with severe hypokalemia and hyponatremia following indapamide use for treatment of hypertension and highlighted the potential role of hyponatremia in the pathogenesis of the acquired form of Brugada syndrome.
No takes yet. Share an insight, caveat, or question.
Mok et al. (2008) conducted a case report in Concomitant-acquired Long QT and Brugada syndromes (n=1). Indapamide was evaluated on Concomitant-acquired Long QT and Brugada syndromes. Indapamide-induced severe hypokalemia and hyponatremia were associated with the development of concomitant-acquired Long QT and Brugada syndromes in 1 patient.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: